Chargement en cours...
Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy
Therapy with immune checkpoint inhibitors (ICIs) has improved overall survival and cancer-related morbidity of cancer treatment even in cancer entities with poor prognosis. Since the approval of the first ICI, ipilimumab, for treatment of advanced melanoma by the Food and Drug Administration (FDA) i...
Enregistré dans:
| Publié dans: | J Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Hindawi
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7749779/ https://ncbi.nlm.nih.gov/pubmed/33381178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8865054 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|